BTK inhibitors

Image comparing healthy and degraded myelin sheath

Roche reports phase 3 multiple sclerosis wins for BTK inhibitor

One win was based on the finding that the therapy was non-inferior to Ocrevus, despite the company originally designing the study to show superiority.

Nick Paul Taylor Nov 10, 2025 6:26am

Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay

Sep 22, 2025 8:00am

Businessman climbing steps to pluck a star from the sky

Roche links BTK drug to low relapse rate across 96-week MS trial

May 30, 2025 5:19am

Sanofi BTK inhibitor for blood disease raises platelet levels

Nov 5, 2024 1:42pm

positive negative up down good bad mixed

Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies

Sep 20, 2024 7:07am

plan B fail reroute road path trail miss

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

Sep 2, 2024 1:00am